Indian Journal of Urology Users online:10869  
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size

Year : 2009  |  Volume : 25  |  Issue : 3  |  Page : 407-408

Detrusor underactivity: To tone or not to tone the bladder?

Department of Urology, Christian Medical College, Vellore, Tamil Nadu, India

Date of Web Publication1-Oct-2009

Correspondence Address:
Nitin S Kekre
Department of Urology, Christian Medical College, Vellore, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0970-1591.56186

Rights and Permissions


Objectives: The aim of this review was to review the available evidence in literature for the clinical effectiveness of Bethanechol Chloride in patients with detrusor underactivity.
Materials& Methods: We searched all relevant data from Medline and peer-reviewed journals available online on the use of bethanechol in patients with detrusor underactivity.
Results: Most reports that suggest a therapeutic clinical benefit with use of bethanechol have all been anecdotal reports and there is no definite clinical evidence available till date to support its clinical usefulness.
Conclusion: The current available data have shown to offer no definite benefit with the use of parasympathomimetic agents in patients with DU. One of the meta-analysis has shown bethanechol to be ineffective in promoting bladder emptying.

Keywords: Detrusor underactivity, Bethanechol chloride, parasympathomimetics

How to cite this article:
Krishnamoorthy S, Kekre NS. Detrusor underactivity: To tone or not to tone the bladder?. Indian J Urol 2009;25:407-8

How to cite this URL:
Krishnamoorthy S, Kekre NS. Detrusor underactivity: To tone or not to tone the bladder?. Indian J Urol [serial online] 2009 [cited 2022 Dec 1];25:407-8. Available from:

   Background Top

Detrusor underactivity (DU) is a common but highly under diagnosed geriatric condition. The clinical diagnosis is often difficult as the symptoms are non specific and can be diagnosed only by urodynamics. [1] The clinical settings where one encounters the problem of DU are: (i) diabetic bladder, (ii) chronic retention of urine, and (iii) neuro-vesical dysfunction. Some have advocated the use of parasympathomimetic drugs like bethanechol chloride (BC) for the treatment of underactive detrusor with a view to improve the bladder contraction. Are these drugs really beneficial? Is there scientific evidence available to support the efficacy and safety of this drug in the treatment of DU? A literature search has been performed by Pubmed using the key words detrusor underactivity, hypo-contractile detrusor, chronic retention of urine, and bethanechol chloride. This evidence-based review is undertaken to answer the above questions and to assess the quality of evidence to support the use of this drug.

   Detrusor Underactivity Top

DU is defined as reduced strength and/or duration resulting in prolonged bladder emptying and/or a failure to achieve complete bladder emptying in a normal time span. [1] It can occur as a result of either a primary lack of stimulus for detrusor contraction or secondary to defective tissue responsiveness. The primary stimulus for detrusor contraction is acetyl choline, which acts on muscarinic (M3) receptors of the bladder musculature. Lack of acetyl choline can lead to a defective contraction of the bladder musculature, resulting in detrusor underactivity. [2]

With ageing, the cholinergic mechanism becomes defective while the neural pathway and the bladder musculature still remain normal. There is evidence to suggest that such patients might derive some benefit from BC. In cases of muscle loss or axonal degeneration, these drugs will not be effective. [1]

   Evidence-Based Analysis Top

No randomized trials have been conducted to support the use of parasympathomimetics in DU. Barrett, in a double-blind, placebo-controlled, randomized trial studied the effects of oral BC on voiding in patients with chronic retention of urine. No differences in voided volumes, residual volumes, or mean flow rates were observed between the treated and control groups. [3] Of the 13 patients who had complaints of headache, abdominal cramps, and flushing, 9 patients had taken an oral dose of 50 mg of BC or more. They postulated that the side effects might be due to a higher dosage of the drug and that the effects of BC on trigone and bladder neck might also result in an increased frequency of micturition and an increase in the outflow resistance in these patients. Hindley, et al. used oral BC with intra-vesical prostaglandin (PGE2). In their prospective double-blind randomized trial of 19 patients with DU, only 4 out of 9 patients receiving active drug were shown to have symptomatic improvement and were able to reduce the frequency of clean intermittent self catheterization. [4] There were no serious adverse events and all 19 patients could complete the course of treatment. However, the therapeutic effect of this combination had been found to be of limited benefit when compared with the placebo combination.

Diabetes mellitus is the most common cause of sensory dysfunction of the urinary bladder, resulting in sensory and autonomic poly-neuropathy. This results in an impaired sensation of bladder fullness, increased bladder capacity, reduced detrusor contractility, and an increase in the residual volume. [5] BC in such conditions cannot be expected to show any benefit as the primary problem is not a lack of parasympathomimetic agent, but an inherent sensory and a myogenic failure.

Barendrecht, et al. performed a meta-analysis on the efficacy of parasympathomimetics for underactive detrusor. They analyzed ten published studies that used BC, Carbachol, or Distygmine. [6] They concluded that there is little evidence to support the use of parasympathomimetics or acetyl cholinesterase inhibitors in the treatment of DU. The reason for a poor therapeutic response can either be because of the unresponsiveness of the detrusor towards a contractile stimulus as in cases of post pelvic surgeries or because the dosage that is given is too low to induce a therapeutic response. The higher doses of BC produce a slightly higher benefit, but at the cost of enhanced side effects, preventing their further use.

Kemp, et al. supported the claim that BC is beneficial for patients who had undergone Wertheim's hysterectomy, but the number of patients included in this study were too small to derive any valid conclusion. [7] Riedl and his colleagues administered BC in the form of electromotive intra-vesical instillation. [8] In their study of 45 patients with DU, they observed that in patients who had an electromotive instillation, the penetration through urothelium onto the bladder wall was enhanced and elicited a better detrusor contraction. Such a benefit was observed in only a select group of patients.

   Conclusions Top

The current available data have shown no definite benefit with use of parasympathomimetic agents in patients with DU. Moreover, the presence of a pharmacological activity alone should not be considered tantamount to clinical or therapeutic efficacy. Most of the reports that suggest a clinical usefulness of BC have all been anecdotal reports, with no definite clinical evidence to suggest its therapeutic efficacy. The meta-analysis by Barendrecht and his colleagues has clearly shown BC to be ineffective in promoting bladder emptying, regardless of the dosage and route of administration.

   References Top

1.Taylor JA 3rd, Kuchel GA. Detrusor underactivity: Clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc 2006;54:1920-32.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]  
2.Finkbeiner AE. Is bethanechol chloride clinically effective in promoting bladder emptying? A literature review. J Urol 1985;134:443-9.  Back to cited text no. 2      
3.Barrett DM. The effect of oral bethanechol chloride on voiding in female patients with excessive residual urine: a randomized double-blind study. J Urol 1981;126:640-2.  Back to cited text no. 3  [PUBMED]    
4.Hindley RG, Brierly RD, Thomas PJ. Prostaglandin E2 and bethanechol in combination for treating detrusor underactivity. BJU Int 2004;93:89-92.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]  
5.Changolkar AK, Hypolite JA, Disanto M, Oates PJ, Wein AJ, Chacko S. Diabetes induced decrease in detrusor smooth muscle force is associated with oxidative stress and overactivity of aldose reductase. J Urol 2005;173:309-13.  Back to cited text no. 5  [PUBMED]  [FULLTEXT]  
6.Barendrecht MM, Oelke M, Laguna MP, Michel MC. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int 2007;99:749-52.  Back to cited text no. 6  [PUBMED]  [FULLTEXT]  
7.Kemp B, Kitschke HJ, Goetz M, Heyl W. Prophylaxis and treatment of bladder dysfunction after Wertheim-Meigs operation: the positive effect of early postoperative detrusor stimulation using the cholinergic drug betanecholchloride. Int Urogynecol J Pelvic Floor Dysfunct 1997;8:138-41.  Back to cited text no. 7  [PUBMED]    
8.Riedl CR, Stephen RL, Daha LK, Knoll M, Plas E, Pflόger H. Electromotive administration of intravesical bethanechol and the clinical impact on acontractile detrusor management: introduction of a new test. J Urol 2000;164:2108-11.  Back to cited text no. 8      

This article has been cited by
1 Underactive Bladder; Review of Progress and Impact From the International CURE-UAB Initiative
Michael B. Chancellor, Sarah N. Bartolone, Laura E. Lamb, Elijah Ward, Bernadette M.M. Zwaans, Ananias Diokno
International Neurourology Journal. 2020; 24(1): 3
[Pubmed] | [DOI]
2 Advanced therapeutic directions to treat the underactive bladder
Phillip P. Smith,Pradeep Tyagi,George A. Kuchel,Subrata Pore,Christopher Chermansky,Michael Chancellor,Naoki Yoshimura,Peter Levanovich
International Urology and Nephrology. 2014; 46(S1): 35
[Pubmed] | [DOI]
3 The passive and active contractile properties of the neurogenic, underactive bladder
Young, J.S. and Johnston, L. and Soubrane, C. and McCloskey, K.D. and McMurray, G. and Eccles, R. and Fry, C.H.
BJU International. 2013; 111(2): 355-361
4 The passive and active contractile properties of the neurogenic, underactive bladder
John S. Young,Louise Johnston,Camille Soubrane,Karen D. McCloskey,Gordon McMurray,Rachel Eccles,Christopher H. Fry
BJU International. 2013; 111(2): 355
[Pubmed] | [DOI]
5 Muscarinic agonists and antagonists: Effects on the urinary bladder
Sellers, D.J., Chess-Williams, R.
Handbook of Experimental Pharmacology. 2012; 208: 375-400
6 Interest of bethanechol chloride in the treatment of underactive bladder after spinal cord injury. Review of literature and report of three cases [Intérêt du béthanéchol chloride dans le traitementde lhypoactivité détrusorienne chez les patients blessés médullaires. Revue de la littérature et présentation de trois situations]
Lamothe, G. and Genoud, D. and Al-Khodairy, A.
Pelvi-perineologie. 2011; 6(1): 46-53
7 Intrt du bthanchol chloride dans le traitement de lhypoactivit dtrusorienne chez les patients blesss mdullaires. Revue de la littrature et prsentation de trois situations
G. Lamothe,D. Genoud,A. Al-Khodairy
Pelvi-prinologie. 2011; 6(1): 46
[Pubmed] | [DOI]
8 The authors respond
Lindy Wood, Joshua Neumiller, Stephen Setter, Erin Dobbins
The American Journal of Geriatric Pharmacotherapy. 2011; 9(1): 94
[VIEW] | [DOI]


Print this article  Email this article
Previous article Next article


   Next article
   Previous article 
   Table of Contents
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (67 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

    Detrusor Underac...
    Evidence-Based A...

 Article Access Statistics
    PDF Downloaded289    
    Comments [Add]    
    Cited by others 8    

Recommend this journal